Nicotinamide Riboside (NR) — Research Profile

Neither is definitively superior. NR has more published human clinical trials and FDA GRAS status, giving it a stronger safety profile. NMN is one enzymatic step closer to NAD+ in the biosynthesis pathway. Both reliably raise NAD+ levels in humans. Head-to-head comparisons are limited, and many researchers consider them roughly equivalent for practical purposes.

No. Unlike niacin (nicotinic acid), NR does not activate the GPR109A receptor responsible for the uncomfortable flushing response. This is one of the key advantages of NR over traditional niacin for raising NAD+ levels.

Blood NAD+ levels begin rising within hours of the first dose and reach significantly elevated levels within 1-2 weeks of daily supplementation. Trammell et al. (2016) showed dose-dependent NAD+ increases within 24 hours of a single oral dose ^[11]. Sustained benefits for aging-related outcomes likely require months of consistent use.

Oral nicotinamide riboside chloride is the form with human evidence; it is the compound shown to be orally bioavailable and to raise blood NAD+ dose-dependently in people. Other NAD+ precursors such as nicotinamide mononucleotide (NMN) or plain nicotinamide are distinct molecules and should not be assumed to behave identically. There is no human evidence that alternative NR salts or delivery formats outperform standard oral NR chloride.

The one consistently proven effect is that oral NR raises circulating NAD+ dose-dependently in humans. Beyond that, evidence is mixed: it lowered inflammatory cytokines in aged skeletal muscle but produced no gains in strength or mitochondrial function, and in Werner syndrome it improved arterial stiffness and reduced skin-ulcer area. In contrast, it did not meaningfully improve cognition or fatigue in long-COVID or add blood-pressure benefit to exercise, so raising NAD+ has not reliably translated into clinical outcomes in healthy people.

There is no established RDA or optimal dose for NR. Human trials have used 100 to 2000 mg/day, with 1000 mg/day being the most common amount studied for raising NAD+ in older adults and in Werner syndrome, while long-COVID research used 2000 mg/day. Higher doses raise NAD+ more but have not been shown to yield proportionally greater clinical benefit.

No trial has directly compared morning versus evening dosing, so an optimal time of day is not established. Studies have simply given the daily amount as a single once-daily dose (for example 1000 mg once daily in Werner syndrome) or split it across the day, both of which raised NAD+. Choose a schedule you can sustain; if NR causes any stomach upset, taking it with food is a reasonable adjustment.

NR is well tolerated in trials, with adverse events generally mild and similar to placebo at 1000 mg/day over six weeks. The most reported issue is gastrointestinal discomfort; in one small peripheral-artery-disease study a participant discontinued 1 g/day for this reason. Notably, because NR is not nicotinic acid, it does not produce the skin flushing associated with high-dose niacin.

No specific drug interactions for NR have been characterized, and the NIH niacin fact sheet lists none for nicotinamide riboside. Clinical trials at up to 2000 mg/day report good tolerability, but they were not designed to detect drug interactions and often excluded people on certain medications. Because dedicated interaction studies do not exist, anyone taking prescription drugs should treat NR's interaction profile as unstudied rather than confirmed safe.

NR has been studied mainly in healthy middle-aged and older adults as a way to counter the decline in NAD+ that accompanies aging, and it dependably raises NAD+ in this group. The clearest clinical signal is in the rare progeroid disorder Werner syndrome, where it improved arterial stiffness and skin ulcers; general anti-aging or performance benefits remain unproven. It has not been tested in pregnancy or breastfeeding, so those groups should avoid it, and anyone considering it should view it as a promising but not yet outcome-validated supplement.

NR raises NAD+ quickly but produces measurable clinical results slowly, if at all. A single oral dose (100-1000 mg) increases blood NAD+ within about 4 hours, up to roughly 2.7-fold, and levels stay elevated across weeks of daily use in blood and muscle. Downstream effects are far less predictable: even after 6 weeks at 1000 mg/day NAD+ rose reliably yet blood-pressure and physical benefits were only exploratory, and 20 weeks of 2000 mg/day in long-COVID patients raised NAD+ without significant cognitive or fatigue improvement.

Controlled human data extend to about six months and show good tolerability, but true long-term safety is not established. NR at 1000 mg/day was well tolerated over 6 weeks in healthy older adults, and 1000 mg/day for 26 weeks in Werner syndrome patients produced no serious adverse events. The longest placebo-controlled use is roughly 20-26 weeks; safety beyond that timeframe has not been studied.

No Tolerable Upper Intake Level (UL) has been set specifically for NR: the NIH niacin UL covers nicotinic acid and nicotinamide and does not address nicotinamide riboside at all. Controlled trials have used up to 2000 mg/day with no drug-related serious adverse events, and a dedicated safety trial found NR chloride well tolerated up to 1000 mg/day for 8 weeks with no flushing, unlike high-dose nicotinic acid. The main dose-related complaint is gastrointestinal upset — one peripheral-artery-disease participant stopped 1 g/day after an episode of diarrhea — so more is not necessarily better.

No dangerous supplement combinations with NR have been documented, and it is commonly stacked with other longevity-oriented ingredients. However, pairing it with an intervention does not guarantee additive benefit: adding 1000 mg/day NR to supervised aerobic exercise for 6 weeks did not lower blood pressure more than exercise plus placebo. Combinations have not been rigorously tested for either added efficacy or safety, so treat stacked products as unproven rather than synergistic.

Essentially all human NR research has used nicotinamide riboside chloride (the patented Niagen material from ChromaDex), so a product listing that specific form matches what was actually studied. Prioritize labels that state the NR chloride dose per serving and carry third-party purity/identity testing, since NR is moisture-sensitive and can degrade. Doses in trials ranged from 100 to 2000 mg/day, so match the milligram amount to a studied range rather than to marketing claims.